[en] Background: Pharmaceutical companies offer an increasing number of inhaler devices, whether or not
together with new substances, for maintenance treatment of patients with COPD or asthma. However,
well-designed studies to support these developments are scarce.
Objectives: The aim of this research was to evaluate how far new developments of inhaler devices are
scientifically supported and translate into improvements of patient preferences and/or clinical outcomes.
Methods: A systematic literature review was performed to retrieve randomised controlled trials in patients
with COPD or asthma that studied the in-company evolution of inhaler devices. Results were
tabulated and discussed.
Results: A total of 30 studies were found comparing Respimat® vs. HandiHaler®, Diskus®(Accuhaler®) vs.
Diskhaler®(Rotadisk®) or pMDI, Ellipta® vs. Diskus®(Accuhaler®), Nexthaler® vs. pMDI, or Breezhaler® vs.
Aerolizer®. These studies show that developments of inhaler devices may improve patient satisfaction
but do not lead to demonstrable improvements in clinical efficacy. Current changes of devices are most
commonly parallelled by changes in administration frequency towards once daily treatment. The only
well-documented effect was found for the Respimat® Soft Mist™ Inhaler, which realises a more than 3-
fold lowering of the once-daily tiotropium dose through increased performance of the inhaler device.
There are however, no data on clinical efficacy or safety comparing the two devices at the same dosage.
Conclusions: Future developments of inhaler devices should all require well-designed studies to
demonstrate patient benefit.
Disciplines :
Rheumatology
Author, co-author :
Ninane, Vincent
Vandevoorde, Jan
Cataldo, Didier ; Université de Liège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Derom, Eric
Liistro, Guiseppe
Munghen, Evert
Peché, Rudy
Schlesser, Marc
Verleden, Geert
Vincken, Walter
Language :
English
Title :
New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences
Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for Diagnosis, Management, and Prevention of COPD 2014 www.goldcopd.org/guidelines-global-strategy-for-diagnosis-managment.html Date last updated: 2014. Date last accessed: October 5 2014
Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention 2014 http://www.ginasthma.org Date last updated: 2014. Date last accessed: October 5, 2014
D. Brocklebank, F. Ram, J. Wright, P. Barry, C. Cates, L. Davies, G. Douglas, M. Muers, D. Smith, and J. White Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature Health Technol. Assess. 5 2001 1 149
K.M. Kew, S. Dias, and C.J. Cates Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Cochrane Database. Syst. Rev. 3 2014 CD010844
F.M. Ducharme, C.M. Ni, I. Greenstone, and T.J. Lasserson Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children Cochrane. Database. Syst. Rev. 2010 CD005535
P. Chorao, A.M. Pereira, and J.A. Fonseca Inhaler devices in asthma and COPD-an assessment of inhaler technique and patient preferences Respir. Med. 108 2014 968 975
F. Lavorini Inhaled drug delivery in the hands of the patient J. Aerosol Med. Pulm. Drug Deliv. 27 6 2014 Dec 414 418
M. Cazzola, C.P. Page, L. Calzetta, and M.G. Matera Pharmacology and therapeutics of bronchodilators Pharmacol. Rev. 64 2012 450 504
D. Caillaud, M.C. Le, Y. Martinat, B. Aguilaniu, and D. Pavia A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients Int. J. Chron. Obstruct. Pulmon. Dis. 2 2007 559 565
J.M. Hohlfeld, A. Sharma, J.A. van Noord, P.J. Cornelissen, E. Derom, L. Towse, V. Peterkin, and B. Disse Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease J. Clin. Pharmacol. 54 2014 405 414
M. Ichinose, T. Fujimoto, and Y. Fukuchi Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients Respir. Med. 104 2010 228 236
J.A. van Noord, P.J. Cornelissen, J.L. Aumann, J. Platz, A. Mueller, and C. Fogarty The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients Respir. Med. 103 2009 22 29
R.A. Wise, A. Anzueto, D. Cotton, R. Dahl, T. Devins, B. Disse, D. Dusser, E. Joseph, S. Kattenbeck, M. Koenen-Bergmann, G. Pledger, and P. Calverley Tiotropium Respimat inhaler and the risk of death in COPD N. Engl. J. Med. 369 2013 1491 1501
E.A. Bronsky, D.S. Pearlman, B.F. Pobiner, C. Scott, Y. Wang, and E. Stahl Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices Pediatrics 104 1999 501 506
L.P. Boulet, R. Cowie, P. Johnston, D. Krakovsky, and S. Mark Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group J. Asthma 32 1995 429 436
P. Mahajan, and L. Okamoto Patient satisfaction with the Diskhaler and the Diskus inhaler, a new multidose power delivery system for the treatment of asthma Clin. Ther. 19 1997 1126 1134
W.R. Pieters, R.A. Stallaert, J. Prins, A.P. Greefhorst, H.G. Bosman, U.R. van, A.J. Schreurs, J.L. van Helmond, and P.G. Janssen A study on the clinical equivalence and patient preference of fluticasone propionate 250 microg twice daily via the Diskus/Accuhaler inhaler or the Diskhaler inhaler in adult asthmatic patients J. Asthma 35 1998 337 345
S.P. Galant, B.J. van, A. Finn, G. Gross, W. Pleskow, A. Brown, A.G. Hamedani, and S.M. Harding Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma Ann. Allergy Asthma Immunol. 82 1999 273 280
D.B. Peden, W.E. Berger, M.J. Noonan, M.R. Thomas, V.L. Hendricks, A.G. Hamedani, P. Mahajan, and K.W. House Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma J Allergy Clin. Immunol. 102 1998 32 38
C. Falcoz, J. Horton, A.E. Mackie, S.M. Harding, and P.T. Daley-Yates Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma Clin. Pharmacokinet. 39 suppl. 1 2000 31 37
L.M. Campbell, T.J. Anderson, M.R. Parashchak, C.M. Burke, S.A. Watson, and M.L. Turbitt A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group Respir. Med. 93 1999 236 244
M.E. Broeders, J. Molema, W.C. Hop, and H.T. Folgering Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI Eur. J Clin. Pharmacol 60 2005 837 841
F. Lavorini, P. Geri, L. Mariani, C. Marmai, N.M. Maluccio, M. Pistolesi, and G.A. Fontana Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism Br. J. Clin. Pharmacol. 62 2006 403 411
J. Lotvall, E.D. Bateman, W.W. Busse, P.M. O'Byrne, A. Woodcock, W.T. Toler, L. Jacques, C. Goldfrad, and E.R. Bleecker Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids J. Negat. Results Biomed. 13 2014 9
J. Lotvall, E.R. Bleecker, W.W. Busse, P.M. O'Byrne, A. oodcock, E.M. Kerwin, S. Stone, R. Forth, L. Jacques, and E.D. Bateman Efficacy and safety of fluticasone furoate 100 mug once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial Respir. Med. 108 2014 41 49
M.T. Dransfield, G. Feldman, P. Korenblat, C.F. LaForce, N. Locantore, M. Pistolesi, M.L. Watkins, C. Crim, and F.J. Martinez Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients Respir. Med. 108 8 2014 Aug 1171 1179
A. Woodcock, E.R. Bleecker, J. Lotvall, P.M. O'Byrne, E.D. Bateman, H. Medley, A. Ellsworth, L. Jacques, and W.W. Busse Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial Chest 144 2013 1222 1229
A. Agusti, T.L. de, B.W. De, M.T. Zvarich, N. Locantore, N. Barnes, J. Bourbeau, and C. Crim A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD Eur. Respir. J. 43 2014 763 772
S. Yun Kirby, C.Q. Zhu, E.M. Kerwin, R.H. Stanford, and G. Georges A randomized controlled trial comparing two dry powder inhalers: more patients with COPD prefer Ellipta compared to Diskus based on device-specific attributes Am. J. Respir. Crit. Care Med. 189 2014 A3037
P.M. O'Byrne, E.R. Bleecker, E.D. Bateman, W.W. Busse, A. Woodcock, R. Forth, W.T. Toler, L. Jacques, and J. Lotvall Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Eur. Respir. J. 43 2014 773 782
W.W. Busse, E.R. Bleecker, E.D. Bateman, J. Lotvall, R. Forth, A.M. Davis, L. Jacques, B. Haumann, and A. Woodcock Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial Thorax 67 2012 35 41
F. Kanniess, M. Scuri, S. Vezzoli, C. Francisco, and S. Petruzzelli Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler((R))) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial Pulm. Pharmacol. Ther. 30 2015 121 127
M. Cazzola, F. Bardaro, and E. Stirpe The role of indacaterol for chronic obstructive pulmonary disease (COPD) J. Thorac. Dis. 5 2013 559 566
R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, D. Jack, P. Bleasdale, R. Owen, M. Higgins, and B. Kramer Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
P.J. Barnes, S.J. Pocock, H. Magnussen, A. Iqbal, B. Kramer, M. Higgins, and D. Lawrence Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design Pulm. Pharmacol. Ther. 23 2010 165 171
O. Bauwens, V. Ninane, B. Van de Maele, R. Firth, F. Dong, R. Owen, and M. Higgins 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol Curr. Med. Res. Opin. 25 2009 463 470
J. Beier, K.M. Beeh, L. Brookman, G. Peachey, A. Hmissi, and S. Pascoe Bronchodilator effects of indacaterol and formoterol in patients with COPD Pulm. Pharmacol. Ther. 22 2009 492 496
C. LaForce, P. Korenblat, P. Osborne, F. Dong, and M. Higgins 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol Curr. Med. Res. Opin. 25 2009 2353 2359
W. Vincken, P.R. Dekhuijzen, and P. Barnes The ADMIT series - issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD Prim. Care Respir. J. 19 2010 10 20
P. Chorao, A.M. Pereira, and J.A. Fonseca Inhaler devices in asthma and COPD-an assessment of inhaler technique and patient preferences Respir. Med. 108 2014 968 975
E.L. Toy, N.U. Beaulieu, J.M. McHale, T.R. Welland, C.A. Plauschinat, A. Swensen, and M.S. Duh Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs Respir. Med. 105 2011 435 441
M. Molimard, and P. Colthorpe Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners J. Aerosol Med. Pulm. Drug Deliv. 28 3 2015 Jun 219 228
G.M. Keating Tiotropium respimat((R)) soft mist inhaler: a review of its use in chronic obstructive pulmonary disease Drugs 74 2014 1801 1816
B. Zierenberg Optimizing the in vitro performance of Respimat J. Aerosol Med. 12 suppl. 1 1999 S19 S24
C.R. Jenkins, and R. Beasley Tiotropium Respimat increases the risk of mortality Thorax 68 2013 5 7
G.N. Rootmensen, A.R. van Keimpema, H.M. Jansen, and R.J. de Haan Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method J. Aerosol Med. Pulm. Drug Deliv. 23 2010 323 328
P.J. Atkins Dry powder inhalers: an overview Respir. Care 50 2005 1304 1312
R. Pavkov, S. Mueller, K. Fiebich, D. Singh, F. Stowasser, G. Pignatelli, B. Walter, D. Ziegler, M. Dalvi, J. Dederichs, and I. Rietveld Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol Curr. Med. Res. Opin. 26 2010 2527 2533
A. Papi, P.L. Paggiaro, G. Nicolini, A.M. Vignola, and L.M. Fabbri Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Eur. Respir. J. 29 2007 682 689
